62141-26-8

Basic information

• Product Name: (1,4-DIOXA-SPIRO[4.5]DEC-8-YL)-ACETIC ACID ETHYL ESTER
• Synonyms: (1,4-DIOXA-SPIRO[4.5]DEC-8-YL)-ACETIC ACID ETHYL ESTER;ethyl 2-(1,4-dioxaspiro[4.5]decan-8-yl)acetate;1,4-Dioxaspiro[4.5]decane-8-acetic acid, ethyl ester;Ethyl 1,4-dioxaspiro[4.5]decane-8-acetate;(1,4-DIOXA-SPIRO[4.5]DEC-8-YL)-ACETIC ACID ETHYL ESTER-25;Ethyl 2-(1,4-dioxaspiro[4.5]dec-8-yl)acetate
• CAS NO: 62141-26-8
• Molecular Formula: C₁₂H₂₀O₄
• Molecular Weight: 228.28
• Product Categories: Miscellaneous
• Mol File: 62141-26-8.mol

Chemical Properties

• Boiling Point: 308.4±17.0 °C(Predicted)
• Appearance: /
• Density: 1.10±0.1 g/cm3(Predicted)
• CAS DataBase Reference: (1,4-DIOXA-SPIRO[4.5]DEC-8-YL)-ACETIC ACID ETHYL ESTER(CAS DataBase Reference)
• NIST Chemistry Reference: (1,4-DIOXA-SPIRO[4.5]DEC-8-YL)-ACETIC ACID ETHYL ESTER(62141-26-8)
• EPA Substance Registry System: (1,4-DIOXA-SPIRO[4.5]DEC-8-YL)-ACETIC ACID ETHYL ESTER(62141-26-8)

Safety Data

• Hazardous Substances Data: 62141-26-8(Hazardous Substances Data)

Usage

Uses

Used in Flavoring and Fragrance Industry:
(1,4-DIOXA-SPIRO[4.5]DEC-8-YL)-ACETIC ACID ETHYL ESTER is used as a flavoring agent and fragrance ingredient for its unique aromatic properties, adding to the sensory experience of various consumer products.
Used in Perfume Production:
In the perfume industry, (1,4-DIOXA-SPIRO[4.5]DEC-8-YL)-ACETIC ACID ETHYL ESTER is used as a component in creating complex and appealing scents, contributing to the overall composition of perfumes.
Used in Soap Making:
(1,4-DIOXA-SPIRO[4.5]DEC-8-YL)-ACETIC ACID ETHYL ESTER is utilized in the production of soaps, where it imparts pleasant odors and enhances the sensory appeal of the product.
Used in Cleaning Products:
(1,4-DIOXA-SPIRO[4.5]DEC-8-YL)-ACETIC ACID ETHYL ESTER is also used in the formulation of cleaning products, where it serves to provide a fresh scent and improve the overall user experience.
Safety Precautions:
It is important to handle (1,4-DIOXA-SPIRO[4.5]DEC-8-YL)-ACETIC ACID ETHYL ESTER with care, as it may cause irritation to the skin, eyes, and respiratory system upon exposure. Proper safety measures should be taken to minimize potential health risks during its use in various applications.

Upstream product

• 51656-91-8 ethyl 1,4-dioxaspiro[4,5]dec-8-ylideneacetate 
• 4746-97-8 cyclohexanedione monoethylene ketal 
• 867-13-0 diethoxyphosphoryl-acetic acid ethyl ester 

Downstream Products

• 135761-76-1 2-(1,4-dioxaspiro[4.5]decan-8-yl)ethanol 
• 58012-34-3 ethyl 4-oxocyclohexaneacetate 
• 204245-53-4 2-(1,4-dioxaspiro[4,5]dec-8-yl)-1-(4-phenyl-1-piperazinyl)ethanone 
• 32863-01-7 4-(2-hydroxyethyl)cyclohexan-1-one 
• 606122-74-1 (4-oxocyclohexyl)acetaldehyde 
• 143949-17-1 2-[1-Hydroxy-meth-(Z)-ylidene]-4-((E)-penta-2,4-dienyl)-cyclohexanone 
• 143948-96-3 Benzoic acid 2-oxo-5-((E)-penta-2,4-dienyl)-cyclohex-(E)-ylidenemethyl ester 
• 135761-80-7 6-(2-acetoxyethyl)-4-(2-azidophenyl)-5,6,7,8-tetrahydroquinolin-8-one 
• 128350-18-5 4-(2-acetoxyethyl)-2,6-bis(2-azidobenzylidene)cyclohexanone 
• 135761-79-4 6-(2-acetoxyethyl)-8-(2-azidobenzylidene)-4-(2-azidophenyl)-5,6,7,8-tetrahydroquinoline 
• 135761-88-5 4-(2-azidophenyl)-6-(2-aminoethyl)-5,6,7,8-tetrahydroquinolin-8-one ethylene ketal 
• 135761-85-2 4-(2-azidophenyl)-6-(2-hydroxyethyl)-5,6,7,8-tetrahydroquinolin-8-one ethylene ketal 
• 135761-91-0 4-(2-azidophenyl)-6-<2-<(3-methylbut-2-enoyl)amino>ethyl>-5,6,7,8-tetrahydroquinolin-8-one 
• 135761-92-1 4-(2-azidophenyl)-6-<2-((E)-2-methylbut-2-enoylamino)ethyl>-5,6,7,8-tetrahydroquinolin-8-one 

Relevant articles and documents

Harnessing Additional Capability from in Water Reaction Conditions: Aldol versus Knoevenagel Chemoselectivity

Aldol reaction chemoselectivity, racemic or enantioselective, has not been previously demonstrated in the presence of Knoevenagel active functional groups. Here, we show that unhindered β-diketones remain unreacted while a ketone moiety undergoes a highly

MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE

Provided are IDO1 inhibitor compounds of Formula (I) and pharmaceutically acceptable salts thereof, their pharmaceutical compositions, their methods of preparation, and methods for their use in the prevention and/or treatment of diseases.

INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE AND METHODS OF THEIR USE

There are disclosed compounds that modulate or inhibit the enzymatic activity of indoleamine 2,3 -dioxygenase (IDO), pharmaceutical compositions containing said compounds and methods of treating proliferative disorders, such as cancer, viral infections and/or inflammatory disorders utilizing the compounds of the invention.

DOPAMINE D3 RECEPTOR ANTAGONISTS HAVING A BICYCLO MOIETY

The disclosure provides compounds having formula (I), wherein the substituents are as defined herein. The compounds are useful for modulating the dopamine D3 receptor and for treating conditions associated therewith, such as addictions, drug dependency, and psychiatric conditions.

INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE AND METHODS OF THEIR USE

There are disclosed compounds that modulate or inhibit the enzymatic activity of indoleamine 2,3-dioxygenase (IDO), pharmaceutical compositions containing said compounds and methods of treating proliferative disorders, such as cancer, viral infections and/or inflammatory disorders utilizing the compounds of the invention.

IMMUNOREGULATORY AGENTS

Compounds that modulate the oxidoreductase enzyme indoleamine 2,3- dioxygenase, and compositions containing the compounds, are described herein. The use of such compounds and compositions for the treatment and/or prevention of a diverse array of diseases, disorders and conditions, including cancer- and immune-related disorders, that are mediated by indoleamine 2,3-dioxygenase is also provided.

IMMUNOREGULATORY AGENTS

Compounds that modulate the oxidoreductase enzyme indoleamine 2,3- dioxygenase, and compositions containing the compounds, are described herein. The use of such compounds and compositions for the treatment and/or prevention of a diverse array of diseases, disorders and conditions, including cancer- and immune-related disorders, that are mediated by indoleamine 2,3-dioxygenase is also provided.

IMMUNOREGULATORY AGENTS

Compounds that modulate the oxidoreductase enzyme indoleamine 2,3- dioxygenase, and compositions containing the compounds, are described herein. The use of such compounds and compositions for the treatment and/or prevention of a diverse array of diseases,

Hydroxypurine compound and use thereof

The invention discloses a hydroxypurine compound and a use of the hydroxypurine compound as a PDE2 or TNFa inhibitor and concretely discloses a compound shown in the formula (I) and its tautomer or pharmaceutically acceptable salt.

Design, Synthesis, and Biological Evaluation of First-in-Class Dual Acting Histone Deacetylases (HDACs) and Phosphodiesterase 5 (PDE5) Inhibitors for the Treatment of Alzheimer's Disease

Simultaneous inhibition of phosphodiesterase 5 (PDE5) and histone deacetylases (HDAC) has recently been validated as a potentially novel therapeutic approach for Alzheimer's disease (AD). To further extend this concept, we designed and synthesized the first chemical series of dual acting PDE5 and HDAC inhibitors, and we validated this systems therapeutics approach. Following the implementation of structure- and knowledge-based approaches, initial hits were designed and were shown to validate our hypothesis of dual in vitro inhibition. Then, an optimization strategy was pursued to obtain a proper tool compound for in vivo testing in AD models. Initial hits were translated into molecules with adequate cellular functional responses (histone acetylation and cAMP/cGMP response element-binding (CREB) phosphorylation in the nanomolar range), an acceptable therapeutic window (>1 log unit), and the ability to cross the blood-brain barrier, leading to the identification of 7 as a candidate for in vivo proof-of-concept testing (Cuadrado-Tejedor, M.; Garcia-Barroso, C.; Sánchez-Arias, J. A.; Rabal, O.; Mederos, S.; Ugarte, A.; Franco, R.; Segura, V.; Perea, G.; Oyarzabal, J.; Garcia-Osta, A. Neuropsychopharmacology 2016, in press, doi: 10.1038/npp.2016.163).